309 related articles for article (PubMed ID: 11409035)
21. Secretase as a target for Alzheimer's disease.
Wolfe MS
Curr Top Med Chem; 2002 Apr; 2(4):371-83. PubMed ID: 11966461
[TBL] [Abstract][Full Text] [Related]
22. The presenilins in Alzheimer's disease--proteolysis holds the key.
Haass C; De Strooper B
Science; 1999 Oct; 286(5441):916-9. PubMed ID: 10542139
[TBL] [Abstract][Full Text] [Related]
23. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
24. Amyloid metabolism and secretases in Alzheimer's disease.
Xia W
Curr Neurol Neurosci Rep; 2001 Sep; 1(5):422-7. PubMed ID: 11898552
[TBL] [Abstract][Full Text] [Related]
25. Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease.
Vardy ER; Catto AJ; Hooper NM
Trends Mol Med; 2005 Oct; 11(10):464-72. PubMed ID: 16153892
[TBL] [Abstract][Full Text] [Related]
26. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity.
Wolfe MS; Xia W; Ostaszewski BL; Diehl TS; Kimberly WT; Selkoe DJ
Nature; 1999 Apr; 398(6727):513-7. PubMed ID: 10206644
[TBL] [Abstract][Full Text] [Related]
27. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
28. Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta-secretase activity in chromaffin vesicles.
Hook VY; Toneff T; Aaron W; Yasothornsrikul S; Bundey R; Reisine T
J Neurochem; 2002 Apr; 81(2):237-56. PubMed ID: 12064471
[TBL] [Abstract][Full Text] [Related]
29. The search for gamma-secretase and development of inhibitors.
Tsai JY; Wolfe MS; Xia W
Curr Med Chem; 2002 Jun; 9(11):1087-106. PubMed ID: 12052174
[TBL] [Abstract][Full Text] [Related]
30. Uncovering gamma-secretase.
Steiner H
Curr Alzheimer Res; 2004 Aug; 1(3):175-81. PubMed ID: 15975065
[TBL] [Abstract][Full Text] [Related]
31. Human beta-secretase (BACE) and BACE inhibitors: progress report.
John V
Curr Top Med Chem; 2006; 6(6):569-78. PubMed ID: 16712492
[TBL] [Abstract][Full Text] [Related]
32. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
Pollack SJ; Lewis H
Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
[TBL] [Abstract][Full Text] [Related]
33. Toward the characterization and identification of gamma-secretases using transition-state analogue inhibitors.
Moore CL; Diehl TS; Selkoe DJ; Wolfe MS
Ann N Y Acad Sci; 2000; 920():197-205. PubMed ID: 11193150
[TBL] [Abstract][Full Text] [Related]
34. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
35. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease.
Beher D; Graham SL
Expert Opin Investig Drugs; 2005 Nov; 14(11):1385-409. PubMed ID: 16255678
[TBL] [Abstract][Full Text] [Related]
36. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain.
Dovey HF; John V; Anderson JP; Chen LZ; de Saint Andrieu P; Fang LY; Freedman SB; Folmer B; Goldbach E; Holsztynska EJ; Hu KL; Johnson-Wood KL; Kennedy SL; Kholodenko D; Knops JE; Latimer LH; Lee M; Liao Z; Lieberburg IM; Motter RN; Mutter LC; Nietz J; Quinn KP; Sacchi KL; Seubert PA; Shopp GM; Thorsett ED; Tung JS; Wu J; Yang S; Yin CT; Schenk DB; May PC; Altstiel LD; Bender MH; Boggs LN; Britton TC; Clemens JC; Czilli DL; Dieckman-McGinty DK; Droste JJ; Fuson KS; Gitter BD; Hyslop PA; Johnstone EM; Li WY; Little SP; Mabry TE; Miller FD; Audia JE
J Neurochem; 2001 Jan; 76(1):173-81. PubMed ID: 11145990
[TBL] [Abstract][Full Text] [Related]
37. Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors.
Weihofen A; Lemberg MK; Friedmann E; Rueeger H; Schmitz A; Paganetti P; Rovelli G; Martoglio B
J Biol Chem; 2003 May; 278(19):16528-33. PubMed ID: 12621027
[TBL] [Abstract][Full Text] [Related]
38. BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis.
Marks N; Berg MJ
Neurochem Res; 2010 Feb; 35(2):181-210. PubMed ID: 19760173
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of BACE, a promising approach to Alzheimer's disease therapy.
Roggo S
Curr Top Med Chem; 2002 Apr; 2(4):359-70. PubMed ID: 11966460
[TBL] [Abstract][Full Text] [Related]
40. Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease.
Wolfe MS; De Los Angeles J; Miller DD; Xia W; Selkoe DJ
Biochemistry; 1999 Aug; 38(35):11223-30. PubMed ID: 10471271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
